Physician profile
Tanuj Nakra
NPI 1366464653
$2,385.90
in general payments reported to CMS, 2019-2025
16 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $250 · 2023: $447 · 2024: $953 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.13 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $362.51 | 2023-2025 | Syfovre |
| Horizon Therapeutics Plc | $274.08 | 2022-2023 | Tepezza |
| Glaukos Corporation | $165.84 | 2024 | |
| Sight Sciences, INC. | $149.94 | 2024 | Omni Surgical System |
| Genentech USA, INC. | $138.05 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $131.62 | 2024 | |
| Rxsight INC | $127.22 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $121.95 | 2021 | |
| Optos, INC. | $98.66 | 2021 | |
| Allergan, INC. | $88.33 | 2022 | |
| Amgen INC. | $38.54 | 2024-2025 | Tepezza |
| Galderma Laboratories, L.P. | $37.34 | 2021-2024 | |
| Integra Lifesciences Corporation | $28.87 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Tarsus Pharmaceuticals, INC. | $28.57 | 2024 | Xdemvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $25.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanuj Nakra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.